Mohammad Naqi

机构：National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, University of Kufa

发表论文 11 篇 · 总被引 453 次 · h-index 6

代表论文

• Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus (2021 · Nature Communications · 被引 200)
• Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus (2018 · JCI Insight · 被引 187)
• Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus (2022 · Annals of the Rheumatic Diseases · 被引 25)
• The Aconitate Decarboxylase 1/Itaconate Pathway Modulates Immune Dysregulation and Associates with Cardiovascular Disease Markers and Disease Activity in Systemic Lupus Erythematosus (2024 · The Journal of Immunology · 被引 16)
• 183 A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus (2019 · Abstracts · 被引 13)
• A Multiomic Analysis to Identify Drivers of Subclinical Vascular Disease in Systemic Lupus Erythematosus (2024 · Arthritis & Rheumatology · 被引 8)